13,100 Shares in Prelude Therapeutics Incorporated (NASDAQ:PRLD) Acquired by SG Americas Securities LLC

SG Americas Securities LLC bought a new stake in shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 13,100 shares of the company’s stock, valued at approximately $56,000.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Royal Bank of Canada raised its holdings in shares of Prelude Therapeutics by 67.9% during the third quarter. Royal Bank of Canada now owns 4,200 shares of the company’s stock valued at $28,000 after purchasing an additional 1,699 shares during the last quarter. Renaissance Technologies LLC raised its stake in Prelude Therapeutics by 1.5% during the 1st quarter. Renaissance Technologies LLC now owns 138,500 shares of the company’s stock valued at $789,000 after buying an additional 2,000 shares during the last quarter. Rhumbline Advisers lifted its holdings in shares of Prelude Therapeutics by 13.4% during the 3rd quarter. Rhumbline Advisers now owns 33,815 shares of the company’s stock valued at $104,000 after buying an additional 3,996 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in shares of Prelude Therapeutics by 1.9% in the 3rd quarter. Price T Rowe Associates Inc. MD now owns 313,165 shares of the company’s stock worth $2,071,000 after buying an additional 5,812 shares during the last quarter. Finally, Barclays PLC grew its holdings in shares of Prelude Therapeutics by 120.0% in the third quarter. Barclays PLC now owns 13,316 shares of the company’s stock worth $42,000 after acquiring an additional 7,264 shares during the period. Institutional investors own 79.72% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on PRLD shares. HC Wainwright cut Prelude Therapeutics from a “buy” rating to a “neutral” rating and set a $5.00 target price on the stock. in a research report on Tuesday, February 20th. JMP Securities assumed coverage on shares of Prelude Therapeutics in a research report on Wednesday, March 13th. They set a “mkt outperform” rating and a $7.00 target price for the company.

Prelude Therapeutics Stock Performance

NASDAQ PRLD opened at $3.72 on Monday. The business’s fifty day moving average is $4.42 and its 200 day moving average is $3.64. Prelude Therapeutics Incorporated has a fifty-two week low of $1.66 and a fifty-two week high of $6.89. The company has a market capitalization of $204.30 million, a PE ratio of -1.82 and a beta of 1.51.

Prelude Therapeutics (NASDAQ:PRLD) last posted its quarterly earnings data on Thursday, February 15th. The company reported ($0.47) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.03. On average, sell-side analysts forecast that Prelude Therapeutics Incorporated will post -1.88 EPS for the current year.

About Prelude Therapeutics

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion.